Medicine Description inhiglip 25mg
inhiglip 25mg tablets is a medication that contains alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. This compound acts by blocking the DPP-4 enzyme, which is responsible for degrading incretin hormones. These hormones, particularly GLP-1 (glucagon-like peptide-1), play a significant role in glucose metabolism. By inhibiting DPP-4, alogliptin enhances the levels of incretin hormones, leading to increased insulin secretion and decreased glucagon levels in a glucose-dependent manner. This mechanism helps to improve glycemic control in individuals with type II diabetes, particularly after meals, contributing to better overall blood sugar management.
Indications and Uses of inhiglip 25mg tablets
- Management of type II diabetes mellitus in adult patients.
- Used as an adjunct to diet and exercise to enhance glycemic control.
- Can be administered alone or in combination with other antidiabetic agents.
Side Effects of inhiglip 25mg tablets
- Headache
- Nausea
- Diarrhea
- Upper respiratory infections
- Potential risk of pancreatitis
- Hypoglycemia when used with other antidiabetic medications
Storage and Handling
Store inhiglip 25mg tablets at room temperature, away from moisture and heat. Keep out of reach of children.
Patient Advice and Precautions
Always take inhiglip 25mg tablets as directed by your healthcare provider. Monitor blood sugar levels regularly and report any unusual symptoms such as persistent nausea, abdominal pain, or signs of pancreatitis. Ensure to maintain a balanced diet and engage in regular physical activity to optimize diabetes management. Discuss with your healthcare provider if you experience any side effects or have kidney issues.